More specifically, other tumors/tumor lines have also responded to PI3K and FGFR inhibitors, without having PI3K and/or FGFR mutations or chromosomal rearrangements, and having corresponding mutations did not consistently induce increased sensitivity (35, 37, 42, 43, 46–53). The gene discussed is PIK3CA; the disease is neoplasm.